1. Scrip
  2. >>New Products

AbbVie Doubles Down In IBD With Skyrizi Ulcerative Colitis Approval

 
• By Kevin Grogan

The US major's blockbuster is already well established as a treatment for Crohn’s disease but the latest thumbs-up from the US FDA means Skyrizi is the first interleukin-23 inhibitor approved for both principal types of inflammatory bowel disease.

• Source: Shutterstock

AbbVie Inc.’s defence of its autoimmune disease franchise post-Humira has received another fillip with its blockbuster Skyrizi getting the nod from US regulators for ulcerative colitis (UC).

A week earlier than expected, the US Food and Drug Administration has approved Skyrizi (risankizumab) for adults with moderately to severely active UC, making it the first interleukin-23 inhibitor approved for both principal types of inflammatory bowel disease (IBD) – UC and Crohn’s disease. The drug got the green light for the latter indication back in June 2022 (and in the EU for months later) and is also on the market for psoriasis and psoriatic arthritis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.